HC Wainwright keeps Buy on Nurix and starts coverage of Eikon Therapeutics

what happened

Analysts at HC Wainwright & Co. maintained their Buy rating on Nurix Therapeutics shares with a $36 price target. According to the note, the target implies a 44.3% upside from the October 15 close of $24.95. The firm pointed to the pipeline of drug candidates Bexobrutideg and NX-1607 and to a firm value of about $4.1 billion under a discounted cash flow model.

HC Wainwright also initiated coverage of Eikon Therapeutics with a Buy rating and a $23 target. The implied upside is 205.0% from the October 15 close of $7.54. The analysts highlighted clinical data for lead candidates EIK1001 and EIK1003 in non-small cell lung cancer and the company's single-molecule tracking platform.

According to TradingView, citing Benzinga data, four recent analyst notes on Nurix over the past 30 days set targets between $32 and $35.

why it matters

Notes like these usually move sentiment around small biotech companies rather than their fundamentals. Several firms backing Nurix at once signals a consistent analyst view, although price targets across brokers differ noticeably.

tags

instruments